Estrogen and antiestrogen regulation of cell cycle progression in breast cancer cells
Open accessThe DOI matches its Crossref record; 53 of the 53 references it cites were found in a registry or an index.
Abstract
The central involvement of estrogen in the development of the mammary gland and in the genesis of breast cancer has lent impetus to studies of the links between estrogen action and the cell cycle machinery. Recent studies of the estrogenic regulation of molecules with known roles in the control of G1/S phase progression have resulted in significant advances in understanding these links. Estrogens independently regulate the expression and function of c-Myc and cyclin D1 and the induction of either c-Myc or cyclin D1 is sufficient to recapitulate the effects of estrogen on cell cycle progression. These pathways converge at the activation of cyclin E-Cdk2 complexes. The active cyclin E-Cdk2 complexes are depleted of the cyclin dependent kinase (CDK) inhibitor p21(WAF1/CIP1) because of estrogen-mediated inhibition of nascent p21(WAF1/CIP1). Insulin and estrogen synergistically stimulate cell cycle progression, and the ability of estrogen to antagonize an insulin-induced increase in p21(WAF1/CIP1) gene expression appears to underlie this effect. Antiestrogen treatment of MCF-7 cells leads to an acute decrease of c-Myc expression, a subsequent decline in cyclin D1, and ultimately arrest of cells in a state with features characteristic of quiescence. An antisense-mediated decrease in c-Myc expression results in decreased cyclin D1 expression and inhibition of DNA synthesis, mimicking the effects of antiestrogen treatment and emphasizing the importance of c-Myc as an estrogen/antiestrogen target. These data identify c-Myc, cyclin D1, p21(WAF1/CIP1) and cyclin E-Cdk2 as central components of estrogen regulation of cell cycle progression and hence as potential downstream targets that contribute to the role of estrogen in oncogenesis.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Estrogen receptor activation promotes cell proliferation in estrogen‐responsive tissues (breast and endometrium) [435].”
From Tumor microenvironment signaling and therapeutics in cancer progression (2023) · cites this paper as [435]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
Wong, C.-W., McNally, C., Nickbarg, E., Komm, B. S., & Cheskis, B. J. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.192569699 · Cited by 324
RetractedCDK inhibitors: positive and negative regulators of G1-phase progression
Sherr, C. J., & Roberts, J. M. (1999) · Genes & Development · doi:10.1101/gad.13.12.1501 · Cited by 6,115
The retinoblastoma protein and cell cycle control
Weinberg, R. A. (1995) · Cell · doi:10.1016/0092-8674(95)90385-2 · Cited by 4,862
The β-Catenin/TCF-4 Complex Imposes a Crypt Progenitor Phenotype on Colorectal Cancer Cells
van de Wetering, M., Sancho, E., Verweij, C., de Lau, W., Oving, I., Hurlstone, A., van der Horn, K., Batlle, E., Coudreuse, D., Haramis, A.-P., et al. (2002) · Cell · doi:10.1016/s0092-8674(02)01014-0 · Cited by 2,030
Connections and Regulation of the Human Estrogen Receptor
McDonnell, D. P., & Norris, J. D. (2002) · Science · doi:10.1126/science.1071884 · Cited by 579
The myc Oncogene: arvelouslomplex
(2002) · Advances in Cancer Research · doi:10.1016/s0065-230x(02)84004-0 · Cited by 463
Prall, O. J., Sarcevic, B., Musgrove, E. A., Watts, C. W., & Sutherland, R. L. (1997) · Journal of Biological Chemistry · doi:10.1074/jbc.272.16.10882 · Cited by 444
Self-citationOpposing Action of Estrogen Receptors α and β on Cyclin D1 Gene Expression
Liu, M.-M., Albanese, C., Anderson, C. M., Hilty, K., Webb, P., Uht, R. M., Price, R. H., Pestell, R. G., & Kushner, P. J. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m201829200 · Cited by 422
Myc represses the p21 (WAF1/CIP1) promoter and interacts with Sp1/Sp3
Gartel, A. L., Ye, X., Goufman, E., Shianov, P., Hay, N., Najmabadi, F., & Tyner, A. L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.081074898 · Cited by 417
Rapid Actions of Steroid Receptors in Cellular Signaling Pathways
Cato, A. C. B., Nestl, A., & Mink, S. (2002) · Science's STKE · doi:10.1126/stke.2002.138.re9 · Cited by 369
Research works printed but not linked: 1
- Lai A, Sarcevic B, Prall OW & Sutherland RL 2001 Insulin/IGF-I and estrogen cooperate to stimulate cyclin E-Cdk2 activation and cell cycle progression in MCF-7 breast cancer cells through differential regulation of cyclin E and p21 WAF1/Cip1 . Journal of Biological Chemistry 276 25823-25833.
Cited by
ERBB receptors and cancer: the complexity of targeted inhibitors
Hynes, N. E., & Lane, H. A. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1609 · Cited by 3,313
Enrichment Map: A Network-Based Method for Gene-Set Enrichment Visualization and Interpretation
Merico, D., Isserlin, R., Stueker, O., Emili, A., & Bader, G. D. (2010) · PLoS ONE · doi:10.1371/journal.pone.0013984 · Cited by 2,235
“Most importantly, the overall functional ‘‘landscape’’ fits with the known role of estrogen hormones as activators of cell proliferation [34].”
BackgroundBiological determinants of endocrine resistance in breast cancer
Musgrove, E. A., & Sutherland, R. L. (2009) · Nature Reviews Cancer · doi:10.1038/nrc2713 · Cited by 1,252
Self-citationEstrogen–gut microbiome axis: Physiological and clinical implications
Baker, J. M., Al-Nakkash, L., & Herbst-Kralovetz, M. M. (2017) · Maturitas · doi:10.1016/j.maturitas.2017.06.025 · Cited by 993
Gut Microbiota and Cancer: From Pathogenesis to Therapy
Vivarelli, S., Salemi, R., Candido, S., Falzone, L., Santagati, M., Stefani, S., Torino, F., Banna, G. L., Tonini, G., & Libra, M. (2019) · Cancers · doi:10.3390/cancers11010038 · Cited by 586
Ström, A., Hartman, J., Foster, J. S., Kietz, S., Wimalasena, J., & Gustafsson, J.-Å. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0308319100 · Cited by 534
DNA Oxidation as Triggered by H3K9me2 Demethylation Drives Estrogen-Induced Gene Expression
Perillo, B., Ombra, M. N., Bertoni, A., Cuozzo, C., Sacchetti, S., Sasso, A., Chiariotti, L., Malorni, A., Abbondanza, C., & Avvedimento, E. V. (2008) · Science · doi:10.1126/science.1147674 · Cited by 527
LncRNA HOTAIR enhances ER signaling and confers tamoxifen resistance in breast cancer
Xue, X., Yang, Y. A., Zhang, A., Fong, K.-W., Kim, J., Song, B., Li, S., Zhao, J. C., & Yu, J. (2016) · Oncogene · doi:10.1038/onc.2015.340 · Cited by 432
Kaaks, R., Berrino, F., Key, T., Rinaldi, S., Dossus, L., Biessy, C., Secreto, G., Amiano, P., Bingham, S., Boeing, H., et al. (2005) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/dji132 · Cited by 420
Endogenous Steroid Hormone Concentrations and Risk of Breast Cancer Among Premenopausal Women
Eliassen, A. H., Missmer, S. A., Tworoger, S. S., Spiegelman, D., Barbieri, R. L., Dowsett, M., & Hankinson, S. E. (2006) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djj376 · Cited by 385
Platet, N., Cathiard, A. M., Gleizes, M., & Garcia, M. (2004) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2004.02.001 · Cited by 367
Positive Cross-Regulatory Loop Ties GATA-3 to Estrogen Receptor α Expression in Breast Cancer
Eeckhoute, J., Keeton, E. K., Lupien, M., Krum, S. A., Carroll, J. S., & Brown, M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0746 · Cited by 347
Self-citationFriedenreich, C. M., & Cust, A. E. (2008) · British Journal of Sports Medicine · doi:10.1136/bjsm.2006.029132 · Cited by 345
Shi, B., Liang, J., Yang, X., Wang, Y., Zhao, Y., Wu, H., Sun, L., Zhang, Y., Chen, Y., Li, R., et al. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00162-07 · Cited by 340
Boulay, A., Rudloff, J., Ye, J., Zumstein-Mecker, S., O'Reilly, T., Evans, D. B., Chen, S., & Lane, H. A. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2402 · Cited by 335
Tumor microenvironment signaling and therapeutics in cancer progression
Goenka, A., Khan, F., Verma, B., Sinha, P., Dmello, C. C., Jogalekar, M. P., Gangadaran, P., & Ahn, B. (2023) · Cancer Communications · doi:10.1002/cac2.12416 · Cited by 323
Proteomic Characterization of the Interstitial Fluid Perfusing the Breast Tumor Microenvironment
Celis, J. E., Gromov, P., Cabezón, T., Moreira, J. M. A., Ambartsumian, N., Sandelin, K., Rank, F., & Gromova, I. (2004) · Molecular & Cellular Proteomics · doi:10.1074/mcp.m400009-mcp200 · Cited by 305
Pathways to tamoxifen resistance
Riggins, R. B., Schrecengost, R. S., Guerrero, M. S., & Bouton, A. H. (2007) · Cancer Letters · doi:10.1016/j.canlet.2007.03.016 · Cited by 277
The transcription factor FOXM1 is a cellular target of the natural product thiostrepton
Hegde, N. S., Sanders, D. A., Rodriguez, R., & Balasubramanian, S. (2011) · Nature Chemistry · doi:10.1038/nchem.1114 · Cited by 269
Shi, L., Sun, L., Li, Q., Liang, J., Yu, W., Yi, X., Yang, X., Li, Y., Han, X., Zhang, Y., et al. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017374108 · Cited by 260
Leivonen, S.-K., Mäkelä, R., Östling, P., Kohonen, P., Haapa-Paananen, S., Kleivi, K., Enerly, E., Aakula, A., Hellström, K., Sahlberg, N., et al. (2009) · Oncogene · doi:10.1038/onc.2009.241 · Cited by 243
Ariazi, E. A., Brailoiu, E., Yerrum, S., Shupp, H. A., Slifker, M. J., Cunliffe, H. E., Black, M. A., Donato, A. L., Arterburn, J. B., Oprea, T. I., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-3068 · Cited by 236
Bhardwaj, P., Au, C. C., Benito-Martin, A., Ladumor, H., Oshchepkova, S., Moges, R., & Brown, K. A. (2019) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2019.03.002 · Cited by 233
Roy, P. G., & Thompson, A. M. (2006) · The Breast · doi:10.1016/j.breast.2006.02.005 · Cited by 210
CARM1 Regulates Estrogen-Stimulated Breast Cancer Growth through Up-regulation of E2F1
Frietze, S., Lupien, M., Silver, P. A., & Brown, M. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-1983 · Cited by 205
Targeting steroid hormone receptors for ubiquitination and degradation in breast and prostate cancer
Rodriguez-Gonzalez, A., Cyrus, K., Salcius, M., Kim, K., Crews, C. M., Deshaies, R. J., & Sakamoto, K. M. (2008) · Oncogene · doi:10.1038/onc.2008.320 · Cited by 206
Estrogen and the endometrium: lessons learned from gene expression profiling in rodents and human
Groothuis, P. G., Dassen, H. H. N. M., Romano, A., & Punyadeera, C. (2007) · Human Reproduction Update · doi:10.1093/humupd/dmm009 · Cited by 202
Hua, S., Kallen, C. B., Dhar, R., Baquero, M. T., Mason, C. E., Russell, B. A., Shah, P. K., Liu, J., Khramtsov, A., Tretiakova, M. S., et al. (2008) · Molecular Systems Biology · doi:10.1038/msb.2008.25 · Cited by 186
Dynamic modelling of oestrogen signalling and cell fate in breast cancer cells
Tyson, J. J., Baumann, W. T., Chen, C., Verdugo, A., Tavassoly, I., Wang, Y., Weiner, L. M., & Clarke, R. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3081 · Cited by 189
Therapeutic resistance to anti-oestrogen therapy in breast cancer
Will, M., Liang, J., Metcalfe, C., & Chandarlapaty, S. (2023) · Nature Reviews Cancer · doi:10.1038/s41568-023-00604-3 · Cited by 176
Brufsky, A. M., & Dickler, M. N. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0423 · Cited by 165
Bostner, J., Ahnström Waltersson, M., Fornander, T., Skoog, L., Nordenskjöld, B., & Stål, O. (2007) · Oncogene · doi:10.1038/sj.onc.1210506 · Cited by 172
Hershberger, P. A., Vasquez, A. C., Kanterewicz, B., Land, S., Siegfried, J. M., & Nichols, M. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2694 · Cited by 166
Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer
Cohen, B., Shimizu, M., Izrailit, J., Ng, N. F. L., Buchman, Y., Pan, J. G., Dering, J., & Reedijk, M. (2010) · Breast Cancer Research and Treatment · doi:10.1007/s10549-009-0621-9 · Cited by 159
Das, B., Dobrowolski, C., Luttge, B., Valadkhan, S., Chomont, N., Johnston, R., Bacchetti, P., Hoh, R., Gandhi, M., Deeks, S. G., et al. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1803468115 · Cited by 164
Caldon, C. E., Sergio, C. M., Kang, J., Muthukaruppan, A., Boersma, M. N., Stone, A., Barraclough, J., Lee, C. S., Black, M. A., Miller, L. D., et al. (2012) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-11-0963 · Cited by 151
Self-citationKnockdown of c-Myc expression by RNAi inhibits MCF-7 breast tumor cells growth in vitro and in vivo
Wang, Y.-H., Liu, S., Zhang, G., Zhou, C.-Q., Zhu, H.-X., Zhou, X.-B., Quan, L.-P., Bai, J.-F., & Xu, N.-Z. (2004) · Breast Cancer Research · doi:10.1186/bcr975 · Cited by 153
Steroid Receptors and Cell Cycle in Normal Mammary Epithelium
Anderson, E., & Clarke, R. B. (2004) · Journal of Mammary Gland Biology and Neoplasia · doi:10.1023/b:jomg.0000023584.01750.16 · Cited by 172
Mechanisms of primary and secondary estrogen target gene regulation in breast cancer cells
Bourdeau, V., Deschenes, J., Laperriere, D., Aid, M., White, J. H., & Mader, S. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm945 · Cited by 143
Pierson-Mullany, L. K., & Lange, C. A. (2004) · Molecular and Cellular Biology · doi:10.1128/mcb.24.24.10542-10557.2004 · Cited by 135
Overcoming Endocrine Resistance in Hormone Receptor–Positive Breast Cancer
Al-Fakeeh, A., & Brezden‐Masley, C. (2018) · Current Oncology · doi:10.3747/co.25.3752 · Cited by 140
Sayeed, A., Konduri, S. D., Liu, W., Bansal, S., Li, F., & Das, G. M. (2007) · Cancer Research · doi:10.1158/0008-5472.can-06-3724 · Cited by 146
The role of sex hormones and steroid receptors on female reproductive cancers
Chuffa, L. G. D. A., Lupi, L. A., Costa, A. B., Amorim, J. P. D. A., & Seiva, F. R. F. (2016) · Steroids · doi:10.1016/j.steroids.2016.12.011 · Cited by 159
The gut microbiome and cancer: from tumorigenesis to therapy
Nobels, A., van Marcke, C., Jordan, B. F., Hul, M. V., & Cani, P. D. (2025) · Nature Metabolism · doi:10.1038/s42255-025-01287-w · Cited by 137
Chu, D., Nguyen, T. T. P., Tien, N. L. B., Khoa, T. D., Nguyen, T.-T., Thanh, V. V., Quang, T. L., Bui, L. M., Pham, V.-H., Ngọc, V. T. N., et al. (2019) · Cells · doi:10.3390/cells8080857 · Cited by 133
Creighton, C. J., Cordero, K. E., Larios, J. M., Miller, R. S., Johnson, M. D., Chinnaiyan, A. M., Lippman, M. E., & Rae, J. M. (2006) · Genome biology · doi:10.1186/gb-2006-7-4-r28 · Cited by 122
Vanderlaag, K. E., Hudak, S. A., Bald, L. N., Fayadat‐Dilman, L., Sathe, M., Grein, J., & Janatpour, M. J. (2010) · Breast Cancer Research · doi:10.1186/bcr2586 · Cited by 114
Androgens and androgen receptors in breast cancer
Díaz-Chico, B. N., Rodríguez, F. G., González, A., Ramírez‐Moreno, R., Bilbao, C., de León, A. C., Jaime, A. A., Chirino, R., Navarro, D., & Díaz-Chico, J. C. (2007) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.11.019 · Cited by 125
Jo, E., Kim, S., Ra, J., Kim, S., Cho, S., Jung, J. W., Yang, S.-J., PARK, J., Hwang, J., & Aruoma, O. I. (2005) · Cancer Letters · doi:10.1016/j.canlet.2004.12.038 · Cited by 113
Chen, B., Pan, H., Zhu, L., Deng, Y., & Pollard, J. W. (2005) · Molecular Endocrinology · doi:10.1210/me.2004-0274 · Cited by 113
Al-Dhaheri, M. H., Wu, J., Skliris, G. P., Li, J., Higashimato, K., Wang, Y., White, K. P., Lambert, P. F., Zhu, Y., Murphy, L. C., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-10-2426 · Cited by 103
Martineti, V., Picariello, L., Tognarini, I., Sala, S. C., Gozzini, A., Azzari, C., Mavilia, C., Tanini, A., Falchetti, A., Fiorelli, G., et al. (2005) · Endocrine Related Cancer · doi:10.1677/erc.1.00861 · Cited by 109
Cui, Y., Parra, I., Zhang, M., Hilsenbeck, S. G., Tsimelzon, A., Furukawa, T., Horii, A., Zhang, Z.-Y., Nicholson, R. I., & Fuqua, S. A. W. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-3243 · Cited by 97
Modulating Estrogen Receptor-related Receptor-α Activity Inhibits Cell Proliferation
Bianco, S., Lanvin, O., Tribollet, V., Macari, C., North, S., & Vanacker, J.-M. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.028191 · Cited by 107
Estrogen Inhibits ATR Signaling to Cell Cycle Checkpoints and DNA Repair
Pedram, A., Razandi, M., Evinger, A. J., Lee, E., & Levin, E. R. (2009) · Molecular Biology of the Cell · doi:10.1091/mbc.e09-01-0085 · Cited by 109
Ruo, S. W., Alkayyali, T., Win, M., Tara, A., Joseph, C., Kannan, A., Srivastava, K., Ochuba, O., Sandhu, J. K., Went, T. R., et al. (2021) · Cureus · doi:10.7759/cureus.17472 · Cited by 87
Nuclear EGFR in ductal invasive breast cancer: correlation with cyclin-D1 and prognosis
Hadžisejdić, I., Mustać, E., Jonjić, N., Petković, M., & Grahovac, B. (2010) · Modern Pathology · doi:10.1038/modpathol.2009.166 · Cited by 92
Kaaks, R., Tikk, K., Sookthai, D., Schöck, H., Johnson, T., Tjønneland, A. M., Olsen, A., Overvad, K., Clavel‐Chapelon, F., Dossus, L., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28528 · Cited by 102
Fatty acid synthase regulates estrogen receptor-α signaling in breast cancer cells
Menéndez, J. A., & Lupu, R. (2017) · Oncogenesis · doi:10.1038/oncsis.2017.4 · Cited by 88
Design and synthesis of estrogen receptor degradation inducer based on a protein knockdown strategy
Demizu, Y., Okuhira, K., Motoi, H., Ohno, A., Shoda, T., Fukuhara, K., Okuda, H., Naito, M., & Kurihara, M. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.11.086 · Cited by 91
c-Myc overexpression and endocrine resistance in breast cancer
McNeil, C. M., Sergio, C. M., Anderson, L. R., Inman, C. K., Eggleton, S. A., Murphy, N., Millar, E. K. A., Crea, P., Kench, J. G., Alles, M. C., et al. (2006) · The Journal of Steroid Biochemistry and Molecular Biology · doi:10.1016/j.jsbmb.2006.09.028 · Cited by 86
Self-citationLarnder, A., Manges, A. R., & Murphy, R. A. (2025) · International Journal of Cancer · doi:10.1002/ijc.35427 · Cited by 87
Physical activity and breast cancer risk
Loprinzi, P. D., Cardinal, B. J., Smit, E., & Winters‐Stone, K. M. (2012) · Journal of Exercise Science & Fitness · doi:10.1016/j.jesf.2012.04.004 · Cited by 92
Endocrine Resistance in Breast Cancer
Dixon, J. M. (2014) · New Journal of Science · doi:10.1155/2014/390618 · Cited by 103
Karlsson, E. A., Waltersson, M. A., Bostner, J., Pérez‐Tenorio, G., Olsson, B., Hallbeck, A., & Stål, O. (2011) · Genes Chromosomes and Cancer · doi:10.1002/gcc.20900 · Cited by 84
Patel, H., Tao, N., Lee, K.-M., Huerta-Rosario, M., Arlt, H., Mullarkey, T. L., Troy, S. M., Arteaga, C. L., & Bihani, T. (2019) · Breast Cancer Research · doi:10.1186/s13058-019-1230-0 · Cited by 85
Nomegestrol acetate, a novel progestogen for oral contraception
Mueck, A. O., & Sitruk-Ware, R. L. (2011) · Steroids · doi:10.1016/j.steroids.2011.02.002 · Cited by 87
Obesity and breast cancer in premenopausal women: Current evidence and future perspectives
Laudisio, D., Muscogiuri, G., Barrea, L., Savastano, S., & Colao, A. (2018) · European Journal of Obstetrics & Gynecology and Reproductive Biology · doi:10.1016/j.ejogrb.2018.03.050 · Cited by 87
Minireview: Tipping the Balance: Ligand-Independent Activation of Steroid Receptors
Bennesch, M. A., & Picard, D. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1315 · Cited by 86
Estradiol and the Development of the Cerebral Cortex: An Unexpected Role?
Denley, M. C. S., Gatford, N. J. F., Sellers, K. J., & Srivastava, D. P. (2018) · Frontiers in Neuroscience · doi:10.3389/fnins.2018.00245 · Cited by 88
lncRNA CYTOR promotes tamoxifen resistance in�breast cancer cells via sponging miR‑125a‑5p
Liu, Y., Li, M., Yu, H., & Piao, H. (2019) · International Journal of Molecular Medicine · doi:10.3892/ijmm.2019.4428 · Cited by 95
Rodriguez-Mora, O. G., LaHair, M. M., McCubrey, J. A., & Franklin, R. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0271 · Cited by 65
Brassinosteroids cause cell cycle arrest and apoptosis of human breast cancer cells
Steigerová, J., Oklešťková, J., Levková, M., Rárová, L., Kolář, Z., & Strnad, M. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.09.006 · Cited by 90
DNA methylation age is elevated in breast tissue of healthy women
Sehl, M. E., Henry, J. E., Storniolo, A. M., Ganz, P. A., & Horvath, S. (2017) · Breast Cancer Research and Treatment · doi:10.1007/s10549-017-4218-4 · Cited by 75
Potential Impacts of Prebiotics and Probiotics on Cancer Prevention
Samanta, S. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520621999201210220442 · Cited by 82
Characterizing DNA methylation signatures of retinoblastoma using aqueous humor liquid biopsy
Li, H., Xu, L., Weisenberger, D. J., Li, M., Zhou, W., Peng, C., Stachelek, K., Cobrinik, D. E., Liang, G., & Berry, J. L. (2022) · Nature Communications · doi:10.1038/s41467-022-33248-2 · Cited by 79
Belguise, K., & Sonenshein, G. E. (2007) · Journal of Clinical Investigation · doi:10.1172/jci32424 · Cited by 86
Cell Cycle Genes in Ovarian Cancer
D’Andrilli, G., Kumar, C., Scambia, G., & Giordano, A. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-0886 · Cited by 76
CCR5 blockage by maraviroc: a potential therapeutic option for metastatic breast cancer
Pervaiz, A., Zepp, M., Mahmood, S., Ali, D. M., Berger, M. R., & Adwan, H. (2018) · Cellular Oncology · doi:10.1007/s13402-018-0415-3 · Cited by 76
Zhang, J., Sui, S., Wu, H., Zhang, J., Zhang, X., Xu, S., & Pang, D. (2019) · Cell Death and Disease · doi:10.1038/s41419-019-1835-3 · Cited by 75
Morgan, M. M., Johnson, B. P., Livingston, M. K., Schuler, L. A., Alarid, E. T., Sung, K. E., & Beebe, D. J. (2016) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2016.05.007 · Cited by 75
Gao, A., Sun, T., Ma, G., Cao, J., Hu, Q., Chen, L., Wang, Y., Wang, Q., Sun, J., Wu, R., et al. (2018) · Nature Communications · doi:10.1038/s41467-018-06309-8 · Cited by 82
Han, H. J., Heo, J. S., & Lee, Y. J. (2005) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00222.2005 · Cited by 74
Aaltonen, K., Amini, R., Landberg, G., Eerola, H., Aittomäki, K., Heikkilä, P., Nevanlinna, H. A., & BLOMQVIST, C. P. (2008) · Breast Cancer Research and Treatment · doi:10.1007/s10549-008-9908-5 · Cited by 73
Jiang, J., Slivova, V., & Slíva, D. (2006) · International Journal of Oncology · doi:10.3892/ijo.29.3.695 · Cited by 84
Apoptosis and Autophagy in Breast Cancer Cells following Exemestane Treatment
Amaral, C., Borges, M. C., Melo, S., da Silva, E. J. T., Correia‐da‐Silva, G., & Teixeira, N. A. A. (2012) · PLoS ONE · doi:10.1371/journal.pone.0042398 · Cited by 79
den Hollander, P., Rayala, S. K., Coverley, D., & Kumar, R. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-2336 · Cited by 70
Stoddard, F. R., Brooks, A. D., Eskin, B. A., & Johannes, G. J. (2008) · International Journal of Medical Sciences · doi:10.7150/ijms.5.189 · Cited by 79
Gaddy, V. T., Barrett, J. T., Delk, J. N., Kallab, A. M., Porter, A. G., & Schoenlein, P. V. (2004) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-03-0637 · Cited by 76
Disruption of Protein Kinase A Regulation Causes Immortalization and Dysregulation of D-Type Cyclins
Nadella, K. S., & Kirschner, L. S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-3183 · Cited by 73
Pérez‐Tenorio, G., Berglund, F., Merca, A. E., Nordenskjöld, B. A., Rutqvist, L. E., Skoog, L. K., & Stål, O. (2006) · International Journal of Oncology · doi:10.3892/ijo.28.5.1031 · Cited by 65
Treeck, O., Juhasz-Böess, I., Lattrich, C., Horn, F., Görse, R., & Ortmann, O. (2007) · Breast Cancer Research and Treatment · doi:10.1007/s10549-007-9749-7 · Cited by 70
Inhibition of E2F1 activity and cell cycle progression by arsenic via retinoblastoma protein
Sheldon, L. A. (2017) · Cell Cycle · doi:10.1080/15384101.2017.1338221 · Cited by 65
Légaré, S., & Basik, M. (2016) · Molecular Endocrinology · doi:10.1210/me.2016-1072 · Cited by 63
Ciallella, H. L., Russo, D. P., Aleksunes, L. M., Grimm, F. A., & Zhu, H. (2021) · Environmental Science & Technology · doi:10.1021/acs.est.1c02656 · Cited by 63
Mir, M., Bergamaschi, A., Katzenellenbogen, B. S., & Popescu, G. (2014) · PLoS ONE · doi:10.1371/journal.pone.0089000 · Cited by 62
27-hydroxycholesterol: A novel player in molecular carcinogenesis of breast and prostate cancer
Marwarha, G., Raza, S., Hammer, K. D. P., & Ghribi, O. (2017) · Chemistry and Physics of Lipids · doi:10.1016/j.chemphyslip.2017.05.012 · Cited by 64
Shah, K. N., Wilson, E. A. H., Malla, R., Elford, H. L., & Faridi, J. S. (2015) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-14-0689 · Cited by 69
Hutcheson, I. R., Goddard, L., Barrow, D., McClelland, R. A., Francies, H. E., Knowlden, J. M., Nicholson, R. I., & Gee, J. M. W. (2011) · Breast Cancer Research · doi:10.1186/bcr2848 · Cited by 60
Rezaei, P. F., Fouladdel, S., Ghaffari, S. M., Amin, G., & Azizi, E. (2012) · DARU Journal of Pharmaceutical Sciences · doi:10.1186/2008-2231-20-101 · Cited by 59
Metadata
- Authors
- Doisneau-Sixou, S. F., Sergio, C. M., Carroll, J. S., Hui, R., Musgrove, E. A., & Sutherland, R. L.
- Affiliations
- Garvan Institute of Medical Research (AU)
- Corresponding author
- Sutherland, R L
- Venue
- Endocrine Related Cancer
- Publisher
- Bioscientifica
- Published
- 2003-06-01
- Volume
- 10
- Issue
- 2
- Pages
- 179-186
- ISSN
- 1351-0088 (ISSN-L)
- 1479-6821
- OpenAlex
- W2121155074
- Cited by
- 333
- References
- 53
- Citations by year
- 2026: 2 · 2025: 9 · 2024: 12 · 2023: 16 · 2022: 17 · 2021: 15 · 2020: 8 · 2019: 8 · 2018: 14 · 2017: 9 · 2016: 15 · 2015: 13 · 2014: 17 · 2013: 7 · 2012: 9
- FWCI
- 1.69
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Endocrine Related Cancer (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Medical Research Council
- National Health and Medical Research Council
- Cancer Council NSW
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Endocrinology › Estrogen and related hormone effects
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Breast Cancer Treatment Studies
- Keywords
- estrogen, antiestrogens, breast cancer, cell cycle progression, c-Myc, cyclin D1, p21, cyclin E/CDK2, G1/S phase, MCF-7 cells, quiescence, carcinogenesis, cyclin-dependent kinase inhibitors
- MeSH terms
- Animals, Breast Neoplasms, Cell Cycle, Estrogens, Female, Humans, Cyclins, Proto-Oncogene Proteins c-myc, Protein Serine-Threonine Kinases, Cell Cycle Proteins, Cyclin-Dependent Kinases, Cyclin E, Cyclin D1, Estrogen Receptor Modulators, CDC2-CDC28 Kinases, Cyclin-Dependent Kinase Inhibitor p21, Cyclin-Dependent Kinase 2
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.